MX339852B - Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina. - Google Patents
Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina.Info
- Publication number
- MX339852B MX339852B MX2011004816A MX2011004816A MX339852B MX 339852 B MX339852 B MX 339852B MX 2011004816 A MX2011004816 A MX 2011004816A MX 2011004816 A MX2011004816 A MX 2011004816A MX 339852 B MX339852 B MX 339852B
- Authority
- MX
- Mexico
- Prior art keywords
- oxo
- prolonged release
- release formulations
- pyrrolidine derivative
- relates
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002035 prolonged effect Effects 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960002161 brivaracetam Drugs 0.000 abstract 1
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 abstract 1
- 229960004002 levetiracetam Drugs 0.000 abstract 1
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 abstract 1
- 229950000852 seletracetam Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08105817 | 2008-11-18 | ||
| EP09100312 | 2009-06-02 | ||
| PCT/EP2009/065271 WO2010057870A1 (en) | 2008-11-18 | 2009-11-17 | Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011004816A MX2011004816A (es) | 2011-05-30 |
| MX339852B true MX339852B (es) | 2016-06-15 |
Family
ID=41381618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011004816A MX339852B (es) | 2008-11-18 | 2009-11-17 | Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10172805B2 (enExample) |
| EP (1) | EP2358360B1 (enExample) |
| JP (2) | JP5954890B2 (enExample) |
| KR (1) | KR101689688B1 (enExample) |
| CN (2) | CN102215829B (enExample) |
| AU (1) | AU2009317280B2 (enExample) |
| BR (1) | BRPI0921313A2 (enExample) |
| CA (1) | CA2741041C (enExample) |
| DK (1) | DK2358360T3 (enExample) |
| EA (1) | EA019572B1 (enExample) |
| ES (1) | ES2602604T3 (enExample) |
| HU (1) | HUE032275T2 (enExample) |
| IL (1) | IL212447A (enExample) |
| MX (1) | MX339852B (enExample) |
| PL (1) | PL2358360T3 (enExample) |
| PT (1) | PT2358360T (enExample) |
| WO (1) | WO2010057870A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2346500B1 (en) | 2008-10-16 | 2017-05-17 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| KR101689688B1 (ko) * | 2008-11-18 | 2016-12-26 | 유씨비 파마, 에스.에이. | ２옥소１피롤리딘 유도체를 포함하는 지연 방출형 제형 |
| WO2011107855A2 (en) * | 2010-03-04 | 2011-09-09 | Torrent Pharmaceuticals Limited | Sustained release oral liquid suspension dosage form |
| EP2563339A1 (en) * | 2010-04-29 | 2013-03-06 | Lupin Limited | Controlled release pharmaceutical compositions of brivaracetam |
| US10154988B2 (en) | 2012-11-14 | 2018-12-18 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| CA2904767C (en) | 2013-03-15 | 2022-06-21 | Agenebio, Inc. | Methods and compositions for improving cognitive function |
| US10806717B2 (en) | 2013-03-15 | 2020-10-20 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EA034167B8 (ru) | 2015-05-22 | 2021-04-27 | Эйджинбайо, Инк. | Фармацевтические композиции леветирацетама пролонгированного высвобождения |
| EP3127539A1 (en) * | 2015-08-03 | 2017-02-08 | Latvian Institute Of Organic Synthesis | Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures |
| EP3397253A1 (en) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| CN111407738A (zh) * | 2020-04-03 | 2020-07-14 | 江苏艾立康药业股份有限公司 | 一种布立西坦控释制剂及其制备方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6327424A (ja) | 1986-07-17 | 1988-02-05 | Shionogi & Co Ltd | 徐放性製剤およびその製造法 |
| US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| US5622716A (en) | 1987-02-20 | 1997-04-22 | Farmarc Nederland B.V. | Process for preparing a retard product containing diltiazem for a single daily administration |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| EP0452862B1 (en) * | 1990-04-18 | 1995-07-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Spherical seed cores, spherical granules and process for production thereof |
| JP2558396B2 (ja) * | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
| JPH10182438A (ja) * | 1991-03-07 | 1998-07-07 | Takeda Chem Ind Ltd | 有核散剤 |
| DE19630035A1 (de) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
| US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
| US5997905A (en) | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US8168170B2 (en) * | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
| ZA200505180B (en) | 2002-11-28 | 2006-10-25 | Themis Lab Private Ltd | Process for manufacturing sustained release microbeads containing venlafaxine HCI |
| DE10353186A1 (de) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
| SI21637A (sl) * | 2003-12-23 | 2005-06-30 | LEK farmacevtska dru�ba d.d. | Farmacevtska oblika z nadzorovanim sproščanjem |
| US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| WO2006088864A1 (en) | 2005-02-16 | 2006-08-24 | Elan Pharma International Limited | Controlled release compositions comprising levetiracetam |
| CA2600282A1 (en) * | 2005-03-29 | 2006-10-05 | Roehm Gmbh | Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release |
| WO2006125074A1 (en) * | 2005-05-17 | 2006-11-23 | Brown University Research Foundation | Drug delivery formulations for targeted delivery |
| US20070264346A1 (en) * | 2006-02-16 | 2007-11-15 | Flamel Technologies | Multimicroparticulate pharmaceutical forms for oral administration |
| FR2897267A1 (fr) | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
| EP2041084B1 (en) | 2006-06-08 | 2013-11-06 | UCB Pharma, S.A. | Co-crystals of pyrrolidinones |
| DE102006035549A1 (de) * | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
| NZ575171A (en) * | 2006-08-31 | 2012-04-27 | Aptalis Pharmatech Inc | Drug delivery systems comprising solid solutions of weakly basic drugs |
| CN101801356B (zh) * | 2007-09-21 | 2016-10-19 | 赢创罗姆有限公司 | 耐受乙醇影响的非阿片类的pH依赖性受控释放的药物组合物 |
| WO2009102964A2 (en) * | 2008-02-14 | 2009-08-20 | Nordson Corporation | Apparatus for testing containers, tray for holding cylinders and suction-basedchuck for robotic arm |
| KR101788804B1 (ko) * | 2008-11-18 | 2017-10-20 | 유씨비 파마, 에스.에이. | ２―옥소―１―피롤리딘 유도체를 포함하는 연장 방출 제형 |
| KR101689688B1 (ko) * | 2008-11-18 | 2016-12-26 | 유씨비 파마, 에스.에이. | ２옥소１피롤리딘 유도체를 포함하는 지연 방출형 제형 |
-
2009
- 2009-11-17 KR KR1020117013972A patent/KR101689688B1/ko active Active
- 2009-11-17 JP JP2011543763A patent/JP5954890B2/ja active Active
- 2009-11-17 CN CN200980145828.3A patent/CN102215829B/zh active Active
- 2009-11-17 WO PCT/EP2009/065271 patent/WO2010057870A1/en not_active Ceased
- 2009-11-17 MX MX2011004816A patent/MX339852B/es active IP Right Grant
- 2009-11-17 EP EP09751938.3A patent/EP2358360B1/en active Active
- 2009-11-17 EA EA201100752A patent/EA019572B1/ru unknown
- 2009-11-17 PL PL09751938T patent/PL2358360T3/pl unknown
- 2009-11-17 ES ES09751938.3T patent/ES2602604T3/es active Active
- 2009-11-17 US US13/129,114 patent/US10172805B2/en active Active
- 2009-11-17 AU AU2009317280A patent/AU2009317280B2/en active Active
- 2009-11-17 BR BRPI0921313A patent/BRPI0921313A2/pt not_active IP Right Cessation
- 2009-11-17 PT PT97519383T patent/PT2358360T/pt unknown
- 2009-11-17 CA CA2741041A patent/CA2741041C/en active Active
- 2009-11-17 HU HUE09751938A patent/HUE032275T2/en unknown
- 2009-11-17 DK DK09751938.3T patent/DK2358360T3/en active
- 2009-11-17 CN CN201410407641.9A patent/CN104208714A/zh active Pending
-
2011
- 2011-04-26 IL IL212447A patent/IL212447A/en active IP Right Grant
-
2015
- 2015-03-30 JP JP2015068416A patent/JP2015120756A/ja active Pending
-
2019
- 2019-01-07 US US16/241,184 patent/US20190142759A1/en not_active Abandoned
- 2019-07-12 US US16/509,919 patent/US20200085754A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2741041C (en) | 2015-01-13 |
| IL212447A0 (en) | 2011-06-30 |
| BRPI0921313A2 (pt) | 2015-12-29 |
| CA2741041A1 (en) | 2010-05-27 |
| HK1159503A1 (en) | 2012-08-03 |
| JP2015120756A (ja) | 2015-07-02 |
| DK2358360T3 (en) | 2016-12-12 |
| ES2602604T3 (es) | 2017-02-21 |
| EP2358360A1 (en) | 2011-08-24 |
| PT2358360T (pt) | 2016-11-15 |
| PL2358360T3 (pl) | 2017-02-28 |
| AU2009317280A1 (en) | 2010-05-27 |
| AU2009317280B2 (en) | 2014-03-06 |
| IL212447A (en) | 2016-10-31 |
| US20200085754A1 (en) | 2020-03-19 |
| KR20110089182A (ko) | 2011-08-04 |
| WO2010057870A1 (en) | 2010-05-27 |
| HUE032275T2 (en) | 2017-09-28 |
| EA019572B1 (ru) | 2014-04-30 |
| CN102215829A (zh) | 2011-10-12 |
| MX2011004816A (es) | 2011-05-30 |
| EA201100752A1 (ru) | 2012-01-30 |
| US20190142759A1 (en) | 2019-05-16 |
| JP2012509357A (ja) | 2012-04-19 |
| JP5954890B2 (ja) | 2016-07-20 |
| KR101689688B1 (ko) | 2016-12-26 |
| CN104208714A (zh) | 2014-12-17 |
| CN102215829B (zh) | 2014-12-10 |
| US20110250282A1 (en) | 2011-10-13 |
| EP2358360B1 (en) | 2016-09-14 |
| US10172805B2 (en) | 2019-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2008006528A3 (en) | Pharmaceutical compositions comprising levetiracetam | |
| EA201100752A1 (ru) | Фармацевтические пероральные композиции с пролонгированным высвобождением, включающие производные 2-оксо-1-пирролидина | |
| WO2009117130A3 (en) | Extended release forumulation containing a wax | |
| PT2076119E (pt) | Composição solvente incluindo pelo menos dois solventes, e formulação fitossanitária que inclua a composição referida bem como um composto activo | |
| WO2010021607A3 (en) | Pharmaceutical formulation | |
| IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
| EP2308870A3 (en) | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses | |
| MY157683A (en) | Combination product for controlling parasites on animals | |
| EP2285357B8 (en) | Pharmaceutical compositions comprising brivaracetam | |
| TW200633716A (en) | Compositions and methods for stabilizing active pharmaceutical ingredients | |
| TN2012000147A1 (en) | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | |
| WO2010000877A3 (en) | Formulation with irritation reducing action comprising bisabolol and [6]-paradol | |
| WO2009100441A3 (en) | Depot formulations | |
| WO2010049454A3 (en) | Antimicrobial composition from copepods | |
| MX2007004294A (es) | Composiciones farmaceuticas que comprenden levetiracetam y proceso para su preparacion. | |
| WO2010111640A3 (en) | Anti-influenza formulations and methods | |
| MX2011007267A (es) | Composiciones farmaceuticas que comprenden derivados de 2-oxo-1-pirrolidina. | |
| EA201590805A1 (ru) | Композиция с немедленным и пролонгированным высвобождением | |
| MX356281B (es) | Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina. | |
| MX2011007451A (es) | Composiciones farmaceuticas que comprenden derivados de 2-oxo-1 pirrolidina. | |
| UA103025C2 (ru) | Твердая композиция лекарственного средства замедленного высвобождения | |
| WO2011122872A3 (ko) | 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물 포함 조성물 | |
| WO2010046061A3 (de) | Kosmetische und/oder pharmazeutische zubereitungen | |
| PL1842534T3 (pl) | Tabletki bursztynianu metoprololu o przedłużonym uwalnianiu oraz sposoby ich wytwarzania | |
| CY1109209T1 (el) | Μητρες ανιονικης υδρογελης με ph-εξαρτωμενη τροποιημενη αποδεσμευση ως μεταφορεις φαρμακων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |